Schizophrenia
Conditions
Keywords
Schizophrenia, Adolescents, Treatment, Guidelines
Brief summary
The purpose of this study was to evaluate the applicability and usefulness of the guideline treatment for diagnosis and treatment of adolescents with schizophrenia, also to evaluate the compliance to the treatment according to the guidelines, and to compare the treatment compliance, severity of illness and social functioning of patients treated according to guideline treatment vs patients with the treatment as usual on a six month follow up.
Detailed description
The drug treatment of patients on the Guideline Treatment group followed an algorithm, where an atypical antipsychotic must be maintained during 6 weeks before the evaluation of medication change if the PANSS score did not show a reduction of 30% and the patients did not show functional improvement. Clozapine could be administered if two trials of antipsychotics were not effective. Benzodiazepines, antidepressants, anticholinergics or anticonvulsants were allowed for the treatment of comorbid disorders or side effects. The psychosocial treatment included psychoeducation (three 90 min sessions with the family and two 45 min sessions with the patients), followed by a seven 45 min sessions training on social skills which focused on verbal and non-verbal communication, as well as in conversation skills. Patients were also trained in healthy life style habits and were included on a 30 min of exercise in group. TAU included an antipsychotic and the psychosocial treatment decided by the clinician
Interventions
DRUGGuideline treatment (Risperidone, administered orally)
Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group
BEHAVIORALPsychosocial treatment
Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group
DRUGTreatment as Usual (any other antipsychotic)
Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
Sponsors
Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Total score ≥ 70 on the Positive and Negative Syndrome Scale (PANSS) and a score of at least 4 (moderate) on 3 of the follow core items (conceptual disorganization , hallucinatory behavior, suspiciousness, and unusual thought content). * Patients were required to have a score of ≥ 4 symptoms on the Clinical Global Impression Improvement Scale (CGI-S) * Had not received antipsychotic in proper doses/ a regular antipsychotic treatment for at least 4 weeks previous enrollment.
Exclusion criteria
* Unstable medical conditions * Their diagnosis changed during the study * Had a history of substance dependence or substance use (except cannabis), -Females with pregnancy * Refusal to practice contraception during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Responder status, >30% reduction in PANSS score and improvement on CGI score. | six months | Responder status, defined by \>30% reduction in PANSS scores and significant improvement on the CGI score. CGI significant improvement defined as a score of 1 (very much improved), or 2 (much improved). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognition assessed using The MATRICS Consensus Cognitive Battery (MCCB) | six months | Cognition assessed using The MATRICS Consensus Cognitive Battery; includes ten trials evaluating seven cognitive domains; processing speed, verbal learning and visual, verbal working memory and non-verbal reasoning and problem solving, sustained attention, and social cognition. |
| Functional outcomes assessed by the Personal and Social Performance Scale. | six months | Functional outcomes assessed by the Personal and Social Performance Scale. The lowest score represents lack of autonomy in the basic functioning and the highest score reflects excellent performance. |
Outcome results
None listed